Ascendis Pharma A/S (NASDAQ:ASND) Shares Sold by Values First Advisors Inc.

Values First Advisors Inc. trimmed its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 23.4% in the fourth quarter, Holdings Channel.com reports. The fund owned 7,844 shares of the biotechnology company’s stock after selling 2,391 shares during the period. Values First Advisors Inc.’s holdings in Ascendis Pharma A/S were worth $988,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of ASND. Invesco Ltd. raised its position in shares of Ascendis Pharma A/S by 9.3% during the 3rd quarter. Invesco Ltd. now owns 672,126 shares of the biotechnology company’s stock worth $62,938,000 after purchasing an additional 57,413 shares during the last quarter. J.P. Morgan Private Wealth Advisors LLC acquired a new position in shares of Ascendis Pharma A/S during the 3rd quarter worth approximately $1,810,000. Schonfeld Strategic Advisors LLC raised its holdings in Ascendis Pharma A/S by 24.7% in the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 38,900 shares of the biotechnology company’s stock valued at $3,643,000 after acquiring an additional 7,700 shares during the last quarter. Jennison Associates LLC raised its holdings in Ascendis Pharma A/S by 30.6% in the 3rd quarter. Jennison Associates LLC now owns 159,434 shares of the biotechnology company’s stock valued at $14,929,000 after acquiring an additional 37,363 shares during the last quarter. Finally, Brown Advisory Inc. raised its holdings in Ascendis Pharma A/S by 2.7% in the 3rd quarter. Brown Advisory Inc. now owns 510,109 shares of the biotechnology company’s stock valued at $47,767,000 after acquiring an additional 13,227 shares during the last quarter.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on ASND shares. StockNews.com upgraded Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Monday, December 25th. Wells Fargo & Company boosted their price objective on shares of Ascendis Pharma A/S from $196.00 to $260.00 and gave the company an “overweight” rating in a research note on Friday, March 15th. Wedbush boosted their price objective on shares of Ascendis Pharma A/S from $207.00 to $225.00 and gave the company an “outperform” rating in a research note on Thursday, February 8th. Cantor Fitzgerald boosted their price objective on shares of Ascendis Pharma A/S from $152.00 to $173.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. Finally, Citigroup boosted their price objective on shares of Ascendis Pharma A/S from $146.00 to $182.00 and gave the company a “buy” rating in a research note on Thursday, February 8th. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $174.14.

Ascendis Pharma A/S Stock Up 1.8 %

NASDAQ:ASND traded up $2.73 on Friday, reaching $151.17. The stock had a trading volume of 295,863 shares, compared to its average volume of 295,281. The company has a debt-to-equity ratio of 7.39, a quick ratio of 2.50 and a current ratio of 3.56. The company has a 50-day moving average of $145.60 and a 200 day moving average of $118.65. Ascendis Pharma A/S has a 12-month low of $64.33 and a 12-month high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings data on Wednesday, February 7th. The biotechnology company reported ($1.66) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.15) by $0.49. The company had revenue of $148.62 million during the quarter, compared to analysts’ expectations of $97.02 million. Ascendis Pharma A/S had a negative net margin of 180.61% and a negative return on equity of 16,574.15%. Equities research analysts expect that Ascendis Pharma A/S will post -4.16 EPS for the current fiscal year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.